AFM11

DRUG2 trials

Sponsors

Affimed GmbH

Conditions

Leukemia, B-CellRefractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non-Hodgkin Lymphoma

Phase 1

Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL

TerminatedNCT02106091

Affimed GmbHRefractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma

Start: 2014-04-30End: 2018-09-30Updated: 2019-06-18

Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL

TerminatedNCT02848911

Affimed GmbHLeukemia, B-Cell

Start: 2016-10-31End: 2019-04-30Updated: 2019-06-19

Related Papers

Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.

2023-01-039 citations